骨化三醇在慢性肾脏病中应用PPT课件.ppt

原文Alexander Kuhlmann 2004 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally ectomized rat.pdf 原文Alexander Kuhlmann 2004 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally ectomized rat.pdf 原文Alexander Kuhlmann 2004 1,25-Dihydroxyvitamin D3 decreases podocyte loss and podocyte hypertrophy in the subtotally ectomized rat.pdf 原文Ute Schwarz 1998 Effect of 1,25(OH)2 vitamin D3 on glomerulosclerosis in subtotally nephrectomized rats.pdf 原文Vincenzo Panichi 1998 Calcitriol modulates in vivo and in vitro cytokine production A role for intracellular calcium.pdf * Vincenzo Panichi 1998 Calcitriol modulates in vivo and in vitro cytokine production A role for intracellular calcium.pdf Vincenzo Panichi 1998 Calcitriol modulates in vivo and in vitro cytokine production A role for intracellular calcium.pdf * * 骨化三醇3除经典的的抑制继发性甲旁亢，调节血钙磷作用外。研究发现活性维生素还具有减少CKD患者尿蛋白的作用。 Agarwal等对220例伴有继发性甲状旁腺功能亢进的3-4期慢性肾脏病（CKD）患者进行为期24周的随机、双盲和安慰剂对照研究，治疗组口服骨化三醇（帕立骨化醇）（9.5μg/周），对照组口服安慰剂。 基线水平蛋白尿患者57例口服活性维生素D，61例口服安慰剂，结果发现，口服骨化三醇患者29/57（51%）尿蛋白明显减少，而口服安慰剂的患者仅有15/61（25%）尿蛋白减少，且口服骨化三醇组蛋白尿的降低幅度为安慰剂组的3.2倍。 骨化三醇降低CKD患者蛋白尿与患者年龄、性别、种族、糖尿病、高血压及RAS系统的阻断无关。 该研究证实，骨化三醇降低CKD患者蛋白尿的作用独立于RAS系统的阻断，骨化三醇作为可能的降低CKD患者蛋白尿治疗手段有待进一步研究 * * 研究者报道骨化三醇可降低IgA肾病患者的蛋白尿，发表于2008年美国肾脏病杂志上。 共纳入10例经活检证实为IgA肾病的患者，持续的蛋白尿经ACEI或ARB治疗无效，接受为期12周的骨化三醇治疗，治疗后骨化三醇组蛋白尿比对照组显著下降（P=0.004） Oral Calcitriol for the Treatment of Persistent Proteinuria in Immunoglobulin A Nephropathy摘要.doc Meta摘要.doc Philippe Autier,2007 Vitamin D Supplementation and Total Mortality.pdf Abigail B. Shoben 2008 Association of Oral Calcitriol with Improved Survival in Nondialyzed CKD.pdf（骨化三醇降低CKD非透析死亡率） Csaba P. Kovesdy 2008 Association of Activated Vitamin D Treatment and Mortality in Chronic Kidney Disease.pdf（骨化三醇延长非透析患者生存率） Praveen Kandula 2011 Vitamin D Supplementation in Chronic Kidney Disease A Systematic Review and Meta-Analysis of Observational Studies and Randomized Controlled Trials.